Prevalence and Risk Factors of Active Tuberculosis in Patients with Rheumatic Diseases: a Multi-Center, Cross-Sectional Study in China
Xiaoqing Liu,Lifan Zhang,Fengchun Zhang,Xiaofeng Zeng,Yan Zhao,Qian Wang,Shengyun Liu,Xiaoxia Zuo,Zhiyi Zhang,Huaxiang Wu,Sheng Chen,Hongbin Li,Ping Zhu,Lijun Wu,Wencheng Qi,Yi Liu,Miaojia Zhang,Huaxiang Liu,Dong Xu,Wenjie Zheng,Yueqiu Zhang,Xiaochun Shi,Lishuai Han,Yaou Zhou,Yanping Zhao,Wenwen Wang,Ting Li,Ning Tie,Kui Zhang,Cainan Luo,Baoqi Gong,Yi Zhao,Chengyin Lv,Lijun Song,Qingjun Wu,Yunyun Fei,Lei Zhang,Hui Luo,Jiaying Sun,Jing Xue,Liyang Gu,Jing Wang,Qing Han,Kuerbanjiang Yimaity,Jiaxin Zhou,Lidan Zhao,Sainan Bian,Wufang Qi,Yanhong Li,Yujing Zhu,Huijun Han,Susu Liao,Gaifen Liu
DOI: https://doi.org/10.1080/22221751.2021.2004864
2021-01-01
Emerging Microbes & Infections
Abstract:Evidence of active tuberculosis (ATB) in patients with rheumatic diseases are research priorities but limited data from China have been reported. Research targeting patients not taking anti-TNF biologics are especially insufficient. We aimed to investigate the prevalence and risk factors of ATB in this at-risk population. We conducted a tertiary hospital-based, multi-center, cross-sectional study by using stratified multi-stage cluster sampling strategy to screen ATB in patients with rheumatic diseases. We estimated the prevalence of ATB in patients with rheumatic diseases and identified risk factors among those who were not taking anti-TNF biologic. A total of 13,550 eligible patients were enrolled, and the result showed the standardized prevalence of ATB according to the composition ratio of various types of rheumatic disease was 882/100000 (95% confidence interval (CI): 706-1057). Multivariable logistic regression analysis in patients not taking anti-TNF biologics showed that the independent risk factors of ATB were having systemic lupus erythematosus (SLE) (OR=2.722, 95% CI: 1.437-5.159, p=0.002), having Behcet’s disease (BD) (OR= 5.261, 95% CI: 2.071-13.365, p<0.001), taking azathioprine(AZA) within the past two years (OR=2.095, 95% CI: 0.986-4.450, p=0.054), exposing to glucocorticoids ≥30mg/d for more than four weeks within the past two years (OR=2.031, 95% CI: 1.247-3.309, p=0.004) and having evidences of previous TB (OR= 6.185, 95% CI: 3.487-10.969, p<0.001). The prevalence of ATB was higher in patients with rheumatic diseases compared to the general population. Patients with SLE or BD, prolonged exposure to moderate to high dose of glucocorticoids and previous TB were independent risk factors for ATB.